RESUMO
UNLABELLED: A randomised phase III study was performed comparing sequential (S) and concurrent (C) chemo-radiotherapy (CRT) in non-small cell lung cancer (NSCLC) patients. METHODS: One hundred and fifty-eight patients were randomised to receive two courses of Gemcitabine (1250mg/m(2) days 1, 8) and Cisplatin (75mg/m(2) day 2) prior to, or daily low-dose Cisplatin (6mg/m(2)) concurrent with radiotherapy, consisting of 24 fractions of 2.75Gy in 32 days, with a total dose of 66Gy. RESULTS: Acute haematological toxicity grade 3/4 was more pronounced in the sequential (S) (30% versus 6%), oesophagitis grade 3/4 more frequent in the concurrent (C) arm (5% versus 14%). Late oesophagitis grade 3 was 4% (S and C), pneumonitis grade 3/4 14% (S) and 18% (C). Because of the poor power of the study no significant differences in median survival (MS), overall survival (OS) and progression-free survival (PFS) could be detected. MS was 16.2 (S) and 16.5 (C) months, 2-year OS was 34% (S) and 39% (C), 3-year OS was 22% (S) and 34% (C). CONCLUSION: Radiotherapy 66Gy given concurrently with daily low-dose Cisplatin or after two courses of Gemcitabine/Cisplatin was well tolerated. Due to early closure no conclusions can be reached on the relative merits; both arms showed good OS.
Assuntos
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Carcinoma Pulmonar de Células não Pequenas/radioterapia , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/radioterapia , Idoso , Terapia Combinada/métodos , Intervalo Livre de Doença , Feminino , Doenças Hematológicas/etiologia , Humanos , Masculino , Pessoa de Meia-Idade , Análise de Sobrevida , Resultado do TratamentoRESUMO
In several pre-clinical models, cyclooxygenase (COX) inhibitors increase radio-sensitivity of tumours, whilst not affecting normal tissues. A randomised phase II trial comparing concurrent radiotherapy with either celecoxib or placebo in patients with stage II-III non-small cell lung cancer was therefore initiated. Because of poor recruitment, the study was stopped after the enrollment of 41 patients, instead of the foreseen 102. None of the endpoints differed significantly between both groups. However, due to the limited number of patients, no definitive conclusions can be drawn.
Assuntos
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Inibidores de Ciclo-Oxigenase/uso terapêutico , Neoplasias Pulmonares/tratamento farmacológico , Pirazóis/uso terapêutico , Radiossensibilizantes/uso terapêutico , Sulfonamidas/uso terapêutico , Adulto , Idoso , Idoso de 80 Anos ou mais , Carcinoma Pulmonar de Células não Pequenas/patologia , Carcinoma Pulmonar de Células não Pequenas/radioterapia , Celecoxib , Quimioterapia Adjuvante , Feminino , Humanos , Neoplasias Pulmonares/patologia , Neoplasias Pulmonares/radioterapia , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Resultado do TratamentoRESUMO
PURPOSE: Target delineation using only CT information introduces large geometric uncertainties in radiotherapy for lung cancer. Therefore, a reduction of the delineation variability is needed. The impact of including a matched CT scan with 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) and adaptation of the delineation protocol and software on target delineation in lung cancer was evaluated in an extensive multi-institutional setting and compared with the delineations using CT only. METHODS AND MATERIALS: The study was separated into two phases. For the first phase, 11 radiation oncologists (observers) delineated the gross tumor volume (GTV), including the pathologic lymph nodes of 22 lung cancer patients (Stages I-IIIB) on CT only. For the second phase (1 year later), the same radiation oncologists delineated the GTV of the same 22 patients on a matched CT-FDG-PET scan using an adapted delineation protocol and software (according to the results of the first phase). All delineated volumes were analyzed in detail. The observer variation was computed in three dimensions by measuring the distance between the median GTV surface and each individual GTV. The variation in distance of all radiation oncologists was expressed as a standard deviation. The observer variation was evaluated for anatomic regions (lung, mediastinum, chest wall, atelectasis, and lymph nodes) and interpretation regions (agreement and disagreement; i.e., >80% vs. <80% of the radiation oncologists delineated the same structure, respectively). All radiation oncologist-computer interactions were recorded and analyzed with a tool called "Big Brother." RESULTS: The overall three-dimensional observer variation was reduced from 1.0 cm (SD) for the first phase (CT only) to 0.4 cm (SD) for the second phase (matched CT-FDG-PET). The largest reduction in the observer variation was seen in the atelectasis region (SD 1.9 cm reduced to 0.5 cm). The mean ratio between the common and encompassing volume was 0.17 and 0.29 for the first and second phases, respectively. For the first phase, the common volume was 0 in 4 patients (i.e., no common point for all GTVs). In the second phase, the common volume was always >0. For all anatomic regions, the interpretation differences among the radiation oncologists were reduced. The amount of disagreement was 45% and 18% for the first and second phase, respectively. Furthermore, the mean delineation time (12 vs. 16 min, p<0.001) and mean number of corrections (25 vs. 39, p<0.001) were reduced in the second phase compared with the first phase. CONCLUSION: For high-precision radiotherapy, the delineation of lung target volumes using only CT introduces too great a variability among radiation oncologists. Implementing matched CT-FDG-PET and adapted delineation protocol and software reduced observer variation in lung cancer delineation significantly with respect to CT only. However, the remaining observer variation was still large compared with other geometric uncertainties (setup variation and organ motion).
Assuntos
Neoplasias Pulmonares/diagnóstico por imagem , Variações Dependentes do Observador , Tomografia Computadorizada de Emissão/métodos , Tomografia Computadorizada por Raios X/métodos , Idoso , Idoso de 80 Anos ou mais , Diagnóstico por Computador , Feminino , Fluordesoxiglucose F18/uso terapêutico , Humanos , Pulmão/diagnóstico por imagem , Linfonodos/diagnóstico por imagem , Masculino , Mediastino/diagnóstico por imagem , Pessoa de Meia-Idade , Compostos Radiofarmacêuticos/uso terapêutico , Parede Torácica/diagnóstico por imagemRESUMO
BACKGROUND AND PURPOSE: To study referral rates and time trends in the use of primary radiotherapy (RT). PATIENTS AND METHODS: The proportion and number of irradiated patients were calculated in a population-based setting among 58,436 cancer patients diagnosed between 1988 and 2002. RESULTS: The number of patients receiving RT within 6 months of diagnosis (RT6mo) increased by about 3.3% annually, the proportion of all incident cases that received RT6mo remained stable (+/-30%). Only 20% of elderly patients (75+) received RT6mo. The proportion of cancer patients that received RT6mo increased markedly between 1988-1992 and 1998-2002 for patients with prostate cancer (15 and 28%, respectively), rectal cancer (33 and 43%) and brain tumours (48 and 67%). The absolute number of irradiated breast cancer patients increased 30% between 1988 and 2002. Among patients with rectal cancer, a shift occurred from postoperative to preoperative RT since 1995. The percentage of irradiated patients with stage I endometrial cancer decreased from 47% in 1988-1992 to 15% in 1998-2002. CONCLUSIONS: The percentage of cancer patients who received primary RT remained stable throughout 1988-2002, being consistently lower for older patients. The increased number of irradiated patients was due mainly to earlier detection and the ageing of the population. To clarify the overall percentage of patients irradiated, population-based studies on RT given after 6 months since diagnosis are warranted.
Assuntos
Neoplasias/radioterapia , Encaminhamento e Consulta/estatística & dados numéricos , Adulto , Fatores Etários , Idoso , Neoplasias Encefálicas/radioterapia , Neoplasias da Mama/radioterapia , Neoplasias do Endométrio/radioterapia , Feminino , Humanos , Neoplasias Pulmonares/radioterapia , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Países Baixos , Vigilância da População , Neoplasias da Próstata/radioterapia , Radioterapia Adjuvante/estatística & dados numéricos , Radioterapia Adjuvante/tendências , Neoplasias Retais/radioterapia , Encaminhamento e Consulta/tendências , Sistema de RegistrosRESUMO
PURPOSE: This phase III randomized trial evaluated survival as well as neurologic and neurocognitive function in patients with brain metastases from solid tumors receiving whole-brain radiation therapy (WBRT) with or without motexafin gadolinium (MGd). PATIENTS AND METHODS: Patients were randomly assigned to 30 Gy of WBRT +/- 5 mg/kg/d MGd. Survival and time to neurologic progression determined by a blinded events review committee (ERC) were coprimary end points. Standardized investigator neurologic assessment and neurocognitive testing were evaluated. RESULTS: Four hundred one (251 non-small-cell lung cancer) patients were enrolled. There was no significant difference by treatment arm in survival (median, 5.2 months for MGd v 4.9 months for WBRT; P =.48) or time to neurologic progression (median, 9.5 months for MGd v 8.3 months for WBRT; P =.95). Treatment with MGd improved time to neurologic progression in patients with lung cancer (median, not reached for MGd v 7.4 months for WBRT; P =.048, unadjusted). By investigator, MGd improved time to neurologic progression in all patients (median, 4.3 months for MGd v 3.8 months for WBRT; P =.018) and in lung cancer patients (median, 5.5 months for MGd v 3.7 months for WBRT; P =.025). MGd improved neurocognitive function in lung cancer patients. CONCLUSION: The overall results did not demonstrate significant differences by treatment arm for survival and ERC time to neurologic progression. Investigator neurologic assessments demonstrated an MGd treatment benefit in all patients. In lung cancer patients, ERC- and investigator-determined time to neurologic progression demonstrated an MGd treatment benefit. MGd may improve time to neurologic and neurocognitive progression in lung cancer.
Assuntos
Antineoplásicos/farmacologia , Neoplasias Encefálicas/radioterapia , Neoplasias Encefálicas/secundário , Cognição , Neoplasias Pulmonares/patologia , Metaloporfirinas/farmacologia , Idoso , Antineoplásicos/administração & dosagem , Neoplasias Encefálicas/tratamento farmacológico , Terapia Combinada , Progressão da Doença , Feminino , Humanos , Masculino , Metaloporfirinas/administração & dosagem , Pessoa de Meia-Idade , Sobrevida , Resultado do TratamentoRESUMO
BACKGROUND AND PURPOSE: To evaluate the process of target volume delineation in lung cancer for optimization of imaging, delineation protocol and delineation software. PATIENTS AND METHODS: Eleven radiation oncologists (observers) from five different institutions delineated the Gross Tumor Volume (GTV) including positive lymph nodes of 22 lung cancer patients (stages I-IIIB) on CT only. All radiation oncologist-computer interactions were recorded with a tool called 'Big Brother'. For each radiation oncologist and patient the following issues were analyzed: delineation time, number of delineated points and corrections, zoom levels, level and window (L/W) settings, CT slice changes, use of side windows (coronal and sagittal) and software button use. RESULTS: The mean delineation time per GTV was 16 min (SD 10 min). The mean delineation time for lymph node positive patients was on average 3 min larger (P = 0.02) than for lymph node negative patients. Many corrections (55%) were due to L/W change (e.g. delineating in mediastinum L/W and then correcting in lung L/W). For the lymph node region, a relatively large number of corrections was found (3.7 corr/cm2), indicating that it was difficult to delineate lymph nodes. For the tumor-atelectasis region, a relative small number of corrections was found (1.0 corr/cm2), indicating that including or excluding atelectasis into the GTV was a clinical decision. Inappropriate use of L/W settings was frequently found (e.g. 46% of all delineated points in the tumor-lung region were delineated in mediastinum L/W settings). Despite a large observer variation in cranial and caudal direction of 0.72 cm (1 SD), the coronal and sagittal side windows were not used in 45 and 60% of the cases, respectively. For the more difficult cases, observer variation was smaller when the coronal and sagittal side windows were used. CONCLUSIONS: With the 'Big Brother' tool a method was developed to trace the delineation process. The differences between observers concerning the delineation style were large. This study led to recommendations on how to improve delineation accuracy by adapting the delineation protocol (guidelines for L/W use) and delineation software (double window with lung and mediastinum L/W settings at the same time, enforced use of coronal and sagittal views) and including FDG-PET information (lymph nodes and atelectasis).
Assuntos
Carcinoma Pulmonar de Células não Pequenas/radioterapia , Neoplasias Pulmonares/radioterapia , Planejamento da Radioterapia Assistida por Computador/instrumentação , Idoso , Idoso de 80 Anos ou mais , Carcinoma Pulmonar de Células não Pequenas/patologia , Estudos de Coortes , Relação Dose-Resposta à Radiação , Desenho de Equipamento , Segurança de Equipamentos , Estudos de Avaliação como Assunto , Feminino , Humanos , Neoplasias Pulmonares/patologia , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Variações Dependentes do Observador , Padrões de Prática Médica , Radioterapia (Especialidade)/normas , Radioterapia (Especialidade)/tendências , Dosagem Radioterapêutica , Planejamento da Radioterapia Assistida por Computador/métodos , Medição de Risco , Sensibilidade e Especificidade , Tomografia Computadorizada por Raios X , Resultado do TratamentoRESUMO
BACKGROUND AND PURPOSE: The EORTC Trial 22881/10882 investigating the role of a boost dose in breast conserving therapy demonstrated a significantly better local control rate with the higher radiotherapy dose, especially in women younger than 50 years of age. This paper investigates the potential impact of the different boost techniques on local control and on fibrosis after breast conserving therapy. PATIENTS AND METHODS: From 1989 to 1996, 2661 patients were randomised to receive a boost dose of 16Gy to the primary tumour bed after microscopically complete tumorectomy and 50Gy whole breast irradiation. The choice of the boost technique was left to the treating investigator. Treatment data were prospectively recorded as well as the clinical outcome in terms of local control and fibrosis. Sixty-three percent of the patients received a boost dose with fast electrons, 28% with photon beams and 9% with interstitial brachytherapy. RESULTS: At 5 years, local recurrences were seen in 74 of the 1635 patients who received an electron boost (4.8%, CI 3.6-5.9%), in 28 of the 753 patients who received a photon boost (4.0%, CI 3.4-5.5%) and in 6 of the 225 patients after an interstitial boost (2.5%, CI 0.3-4.6%). The grade of fibrosis in the whole breast as well as at the primary tumour bed, as scored by the treating radiation oncologist, was similar in the three groups. CONCLUSIONS: Although the three groups are of a rather unequal size, the results of the interstitial boost seem similar in terms of fibrosis and at least as good in terms of local control, despite a lower treatment volume and a longer overall treatment time.
Assuntos
Neoplasias da Mama/radioterapia , Neoplasias da Mama/cirurgia , Mastectomia Segmentar , Recidiva Local de Neoplasia/prevenção & controle , Radioterapia Adjuvante/métodos , Adulto , Idoso , Fracionamento da Dose de Radiação , Elétrons/uso terapêutico , Feminino , Seguimentos , Humanos , Pessoa de Meia-Idade , Fótons/uso terapêutico , Pneumonite por Radiação/prevenção & controle , Resultado do TratamentoRESUMO
Motexafin gadolinium (MGd, PCI-0120, Xcytrin, a metallotexaphyrin developed by Pharmacyclics, is a redox active drug that selectively targets tumour cells with a potential action as a radiosensitiser. In vitro and in vivo models showed radiation enhancement when radiation followed MGd administration. Phase I and II clinical studies showed that MGd was well-tolerated with a maximum-tolerated dose set at 6.3 mg/kg. Acute side effects of discolouration of the sclera, skin and urine are reversible. The clinical efficacy was determined in an international Phase III trial for brain metastases with a significant difference in time to neurological progression for lung cancer brain metastases in favour of MGd and whole brain radiation versus whole brain radiation only. For the treatment of glioblastoma multiforme, promising results are found in a Phase I trial with a median survival of 17.3 months. Further investigation of the combination of MGd and radiotherapy will be worthwhile.
Assuntos
Neoplasias Encefálicas/radioterapia , Glioblastoma/radioterapia , Metaloporfirinas/farmacologia , Radiossensibilizantes/farmacologia , Animais , Humanos , Metaloporfirinas/efeitos adversos , Metaloporfirinas/metabolismo , Metaloporfirinas/uso terapêutico , Metaloporfirinas/toxicidade , Radiossensibilizantes/efeitos adversos , Radiossensibilizantes/metabolismo , Radiossensibilizantes/uso terapêutico , Radiossensibilizantes/toxicidadeRESUMO
PURPOSE: To quantify adequate anisotropic clinical target volume (CTV)-to-planning target volume (PTV) margins for three different setup strategies used during prostate irradiation: (1) no setup corrections, (2) on-line corrections determined from bony anatomy, and (3) on-line corrections determined from gold markers. METHOD AND MATERIALS: Three radiation oncologists independently delineated the CTV on computed tomography images of 30 prostate cancer patients. Eight repeat scans were acquired to allow simulation of the delivered dose distributions in changing geometry. Different registration approaches were taken to mimic the different setup strategies. A surface model-based deformable image registration system was used to warp the delivered dose distributions back to the dose in the planning computed tomography scan. On the basis of the geometric extent of the underdosed areas, a set of anisotropic margins was derived to ensure a minimal dose to the CTV of 95% for 90% of the patients. RESULTS: Without setup correction, margins of approximately 11 mm for the corpus of the prostate and 15 mm for the seminal vesicles were required. These margins could be reduced to 8 and 13 mm when aligning the patient to the bony anatomy and to 3 and 8 mm aligning the patient to implanted gold markers. A larger margin at the apex was required to account for the significant observer variability and steep dose gradients at this location (11 mm using skin marker registration, 9 mm using bony anatomy registration, and 6 mm using gold marker registration). CONCLUSIONS: Novel voxel tracking techniques have enabled us to calculate accumulated dose distributions and design accurate three-dimensional CTV-to-PTV margins for prostate irradiation.
Assuntos
Neoplasias da Próstata/diagnóstico por imagem , Neoplasias da Próstata/radioterapia , Protocolos Clínicos , Humanos , Masculino , Próstata/anatomia & histologia , Próstata/patologia , Neoplasias da Próstata/patologia , Cintilografia , Planejamento da Radioterapia Assistida por Computador , Reprodutibilidade dos Testes , Glândulas Seminais/anatomia & histologia , Glândulas Seminais/diagnóstico por imagem , Pele/patologia , Pele/efeitos da radiação , Tomografia Computadorizada por Raios XRESUMO
PURPOSE: To evaluate the long-term risk of cardiovascular disease (CVD) in survivors of testicular cancer (TC). PATIENTS AND METHODS: We compared CVD incidence in 2,512 5-year survivors of TC, who were treated between 1965 and 1995, with general population rates. Treatment effects on CVD risk were quantified in multivariate Cox regression analysis. RESULTS: After a median follow-up of 18.4 years, 694 cardiovascular events occurred, including 141 acute myocardial infarctions (MIs). The standardized incidence ratio (SIR) for coronary heart disease was 1.17 (95% CI, 1.04 to 1.31), with 14 excess cases per 10,000 person-years. The SIR for MI was significantly increased in nonseminoma survivors with attained ages of less than 45 (SIR = 2.06) and 45 to 54 years (SIR = 1.86) but significantly decreased for survivors with attained ages of 55 years or older (SIR = 0.53). In Cox analysis, mediastinal irradiation was associated with a 3.7-fold (95% CI, 2.2- to 6.2-fold) increased MI risk compared with surgery alone, whereas infradiaphragmatic irradiation was not associated with an increased MI risk. Cisplatin, vinblastine, and bleomycin (PVB) chemotherapy (CT) was associated with a 1.9-fold (95% CI, 1.7- to 2.0-fold) increased MI risk, and bleomycin, etoposide, and cisplatin (BEP) CT was associated with a 1.5-fold (95% CI, 1.0- to 2.2-fold) increased CVD risk and was not associated with increased MI risk (hazard ratio = 1.2; 95% CI, 0.7 to 2.1). Recent smoking was associated with a 2.6-fold (95% CI, 1.8- to 3.9-fold) increased MI risk. CONCLUSION: Nonseminomatous TC survivors experience a moderately increased MI risk at young ages. Physicians should be aware of excess CVD risk associated with mediastinal radiotherapy, PVB CT, and recent smoking. Intervention in modifiable cardiovascular risk factors is especially important in TC survivors. Whether BEP treatment increases CVD risk should be evaluated after more prolonged follow-up.